NEW YORK, April 29 (Reuters) - Gilead Sciences ( GILD )

has reached a $202 million settlement to resolve a civil fraud

lawsuit accusing the company of paying kickbacks to doctors who

agreed to prescribe its HIV drugs, the U.S. attorney's office in

Manhattan said on Tuesday.

The settlement resolves claims that Gilead paid honoraria,

meals and travel expenses to doctors who attended Gilead speaker

events to induce them to prescribe several HIV drugs.

U.S. Attorney Jay Clayton said this violated the federal

False Claims Act by causing claims to be paid by federal

healthcare programs.